Nursing and Midwifery Research Unit, School of Nursing and Midwifery, Queen's University Belfast, UK.
Palliat Med. 2013 Apr;27(4):295-303. doi: 10.1177/0269216312441382. Epub 2012 Mar 26.
Cancer cachexia is a devastating syndrome of advanced malignancy which negatively impacts on patients' morbidity, mortality and quality of life. Chronic inflammation is a key characteristic of cancer cachexia. Therefore, non-steroidal anti-inflammatory drugs (NSAIDs) may be able to break the cycle of cachexia.
To systematically review the literature on the use of NSAIDs for the treatment of cachexia in advanced cancer patients.
All titles retrieved through searching were downloaded to a reference management database, duplicates were removed and the remaining citations were checked for eligibility. Full copies of all eligible articles were obtained and reviewed.
Electronic searches (from inception up to 09/2011) included CINAHL, MEDLINE, EMBASE, and Web of Science. Reference lists from reviewed articles, trial registers and abstracts from relevant conferences were searched. Eligibility criteria were (a) Randomised Controlled Trial; (b) participants were adults with cancer with weight loss or a clinical diagnosis of cachexia; (c) administration of oral NSAIDs.
Four studies were included. These studies provided some evidence of positive therapeutic effect on quality of life, performance status, inflammatory markers, weight gain and survival, but there was insufficient evidence demonstrated for their widespread use in practice.
Insufficient studies have been performed to allow a conclusion to be formed with regard to the effectiveness of NSAIDs in the treatment of cachexia in advanced cancer. Major challenges in this patient cohort include the lack of uniformity of inclusion criteria across studies and the frailty of the patients recruited.
癌症恶病质是一种严重影响晚期恶性肿瘤患者发病率、死亡率和生活质量的综合征。慢性炎症是癌症恶病质的一个主要特征。因此,非甾体类抗炎药(NSAIDs)可能能够打破恶病质的循环。
系统地评价 NSAIDs 治疗晚期癌症患者恶病质的文献。
通过检索获得的所有标题均下载到参考管理数据库中,去除重复项,并检查其余引用的资格。获得并审查所有合格文章的全文。
电子检索(从开始到 2011 年 9 月)包括 CINAHL、MEDLINE、EMBASE 和 Web of Science。从综述文章、试验登记处和相关会议的摘要中检索参考文献列表。纳入标准为:(a)随机对照试验;(b)参与者为患有癌症且有体重减轻或临床恶病质诊断的成年人;(c)口服 NSAIDs 给药。
纳入了四项研究。这些研究提供了一些关于生活质量、功能状态、炎症标志物、体重增加和生存的积极治疗效果的证据,但没有足够的证据表明它们在实践中广泛使用。
由于在晚期癌症患者中 NSAIDs 治疗恶病质的有效性尚未进行充分的研究,因此无法得出结论。在该患者群体中存在的主要挑战包括研究之间纳入标准缺乏一致性以及患者的脆弱性。